Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
108
datasets available to search
ShareScore release 0.9.0
Dataset results
108 results for “Adverse reactions”
Prevention and Pharmacological Management of Cardiac Adverse Drug Reactions Induced by Drugs Used in Oncology.
ClinicalTrials.gov study NCT03678337. IPD Sharing: NO. Countries: 1. Publications: 1.
National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
ClinicalTrials.gov study NCT00414115. IPD Sharing: Not stated. Countries: 1. Publications: 2.
The Influence of Standardized Process Management of Laryngeal Mask Airway Placement Based on Pressure Monitoring on the Incidence of Adverse Reactions in Elderly Patients During the Perioperative Peri
ClinicalTrials.gov study NCT06954857. IPD Sharing: NO. Countries: 1. Publications: 0.
Diagnosing Adverse Drug Reactions Registry
ClinicalTrials.gov study NCT01970709. IPD Sharing: Not stated. Countries: 1. Publications: 15.
Serious Adverse Drug Reaction and Their Preventability
ClinicalTrials.gov study NCT02888834. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions
ClinicalTrials.gov study NCT03387540. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Severe Cutaneous Adverse Reactions in Thailand
ClinicalTrials.gov study NCT02574988. IPD Sharing: NO. Countries: 1. Publications: 6.
Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.
ClinicalTrials.gov study NCT03413176. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Figure 3 from: Ali ZJM, Al-juhiashi AMR (2024) Role of D2 receptor (–141 C Ins/Del) genetic polymorphism on olanzapine-induced adverse drug reaction in schizophrenic patients. Pharmacia 71: 1-8. https://doi.org/10.3897/pharmacia.71.e112064
Figure 3 The Prevalence of D2 receptor alleles rs1799732 (141c ins/del) among both male and female volunteers.
Adverse drug reactions to the three doses of the SARS-COV-2 mRNA-1273 vaccine in a cohort of cancer patients of a tertiary hospital
<p><strong>Introduction:</strong> SARS-CoV-2 vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or underrepresented. Information is scarce regarding safety in this population. </p> <p><strong>Methods:</strong> The objective of this study is to evaluate the safety profile of the mRNA-1273 vaccine across cancer patients and its relationship to patients' demographics. This cross sectional study included patients 18-years or older with solid malignancies receiving active treatment in our hospital who had received the three dose schedule of the mRNA9 1273 vaccine and whose side effects after each dose were recorded. Patient electronic medical records were reviewed retrospectively to collect tha available information in 2021. Patients with documented previous infection by SARS-Cov-2 were excluded from the study.</p> <p><strong>Results:</strong> 93 patients met inclusion criteria. Local adverse drug reactions (ADRs) were reported more frequently after the first and second dose than after the third (41.9%, 43% and 31.1% of the patients respectively), while systemic ADRs were reported less frequently after the first and second dose than after the third (16.1%, 34.4% and 52.6% of the patients respectively). We found a statistically significant association between sex and systemic ADRs after the third dose. Cochran-Armitage test showed a statistically significant linear trend, p = 0.012, with higher ECOG score associated with a lower proportion of patients suffering from systemic side effects. A logistic regression showed that females had 5.79 times higher odds to exhibit systemic ADRs after the third dose (p=0.01) compared to males. Increasing age was associated with a decreased likelihood of exhibiting ADRs (p=0.016).</p> <p><strong>Conclusion:</strong> mRNA-1273 vaccine shows a tolerable safety profile. The likelihood of ADRs appears to be associated with gender and age. Its association with ECOG scores is less evident. Further studies are needed to elucidate this data in cancer patients.<span></span></p>
Ametop - Friend and Foe A Prospective Study of the Incidence of Adverse Reactions With Ametop
ClinicalTrials.gov study NCT02750137. IPD Sharing: NO. Countries: 0. Publications: 2.
Pathogenesis of Adverse Drug Reactions
ClinicalTrials.gov study NCT00224952. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients
ClinicalTrials.gov study NCT05247814. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Effectiveness of Pain Control and Adverse Reactions After Intravenous PCA in Chinese Population
ClinicalTrials.gov study NCT05884021. IPD Sharing: UNDECIDED. Countries: 0. Publications: 9.
Adverse Drug Reactions in Pediatrics: Experience of a Regional Pharmacovigilance Center
ClinicalTrials.gov study NCT03316014. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
ClinicalTrials.gov study NCT01764204. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction
ClinicalTrials.gov study NCT05212610. IPD Sharing: NO. Countries: 1. Publications: 0.
Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction.
ClinicalTrials.gov study NCT03166241. IPD Sharing: Not stated. Countries: 0. Publications: 4.
Evaluating ActionADE in Reducing Adverse Drug Reactions
ClinicalTrials.gov study NCT04568668. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
ClinicalTrials.gov study NCT06322238. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.